{
  "source": "PA-Notification-Vosevi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1232-6\nProgram Prior Authorization/Notification\nMedication Vosevi™ (sofosbuvir, velpatasvir, and voxilaprevir)\nP&T Approval Date 9/2017, 11/2018, 11/2019, 8/2022, 8/2023, 8/2024\nEffective Date 11/1/2024\n1. Background:\nVosevi is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog\nNS5B polymerase inhibitor, velpatasvir, an HCV NS5A inhibitor, and voxilaprevir, an HCV\nNS3/4A protease inhibitor, and is indicated for the treatment of adult patients with chronic HCV\ninfection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have:1\n• Genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen\ncontaining an NS5A inhibitor.\n• Genotype 1a or 3 infection and have previously been treated with an HCV regimen\ncontaining sofosbuvir without an NS5A inhibitor.\nAdditional benefit of Vosevi over Epclusa® (sofosbuvir/velpatasvir) was not shown in\no\nadults with genotype 1b, 2, 4, 5, or 6 infection previously treated with sofosbuvir\nwithout an NS5A inhibitor.\n2. Coverage Criteriaa:\nA. For the treatment of chronic hepatitis C genotype 1, 2, 3, 4, 5 or 6 infection in patients who\nare treatment-experienced with an NS5A inhibitor-based regimen, who are without cirrhosis\nor have compensated cirrhosis, Vosevi will be approved based on all of the following\ncriteria:\n1. Diagnosis of chronic hepatitis C genotype 1, 2, 3, 4, 5 or 6 infection\n-AND-\n2. Patient has prior treatment experience with an HCV NS5A inhibitor [e.g., Daklinza\n(daclatasvir), Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Viekira\n(dasabuvir/ombitasvir/ paritaprevir/ritonavir), Zepatier (elbasvir/grazoprevir)]\n-AND-\n3. One of the following:\na. Patient is without cirrhosis\nb. Patient has compensated cirrhosis (Child-Pugh A)\n-AND-\n4. Patient is not receiving Vosevi in combination with another HCV direct acting antiviral\nagent [e.g., Epclusa (sofosbuvir/velp",
    "out cirrhosis\nb. Patient has compensated cirrhosis (Child-Pugh A)\n-AND-\n4. Patient is not receiving Vosevi in combination with another HCV direct acting antiviral\nagent [e.g., Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Mavyret\n© 2024 UnitedHealthcare Services Inc.\n1\n(glecaprevir/pibrentasvir), Sovaldi (sofosbuvir), Zepatier (elbasvir/grazoprevir)]\nAuthorization will be issued for 12 weeks.\nB. For the treatment of chronic hepatitis C genotype 1a or 3 in patients who are treatment-\nexperienced with a regimen containing Sovaldi (sofosbuvir) without an NS5A inhibitor,\nwho are without cirrhosis or have compensated cirrhosis, Vosevi will be approved based on\nall of the following criteria:\n1. Diagnosis of chronic hepatitis C genotype 1a or 3 infection\n-AND-\n2. Patient has prior treatment experience with a regimen containing Sovaldi (sofosbuvir)\nwithout an NS5A inhibitor\n-AND-\n3. One of the following:\na. Patient is without cirrhosis\nb. Patient has compensated cirrhosis (Child-Pugh A)\n-AND-\n4. Patient is not receiving Vosevi in combination with another HCV direct acting antiviral\nagent [e.g., Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Mavyret\n(glecaprevir/pibrentasvir), Sovaldi (sofosbuvir), Zepatier (elbasvir/grazoprevir)]\nAuthorization will be issued for 12 weeks.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n• Medical necessity may be in place.\n4. References:\n1. Vosevi [package insert]. Foster City, CA: Gilead Sciences, Inc",
    "esses varies by program and/or therapeutic class.\n• Supply limits may be in place.\n• Medical necessity may be in place.\n4. References:\n1. Vosevi [package insert]. Foster City, CA: Gilead Sciences, Inc.; November 2019.\n2. American Association for the Study of Liver Diseases and the Infectious Diseases Society of\nAmerica. Recommendations for Testing, Managing, and Treating Hepatitis C.\nhttp://www.hcvguidelines.org/full-report-view Accessed July 9, 2024.\n© 2024 UnitedHealthcare Services Inc.\n2\nProgram Prior Authorization/Medical Necessity – Vosevi (sofosbuvir,\nvelpatasvir, and voxilaprevir)\nChange Control\nDate Change\n9/2017 New program.\n11/2018 Annual review with no changes to criteria. Updated references.\n11/2019 Annual review with no changes to criteria. Updated references.\n8/2022 Annual review with no changes to criteria. Added Mavyret as example\nof HCV direct acting antiviral agent, removed examples of Sovaldi-\ncontaining regimens and updated references.\n8/2023 Annual review with no changes to the criteria.\n8/2024 Annual review with no changes to the criteria.\n© 2024 UnitedHealthcare Services Inc.\n3"
  ]
}